efgartigimod alfa

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• Argenx jumps on Phase 3 data for blockbuster Vyvgart
  The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments.
  biopharma_dive · 3d ago
• Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositis
  Argenx said Monday that Vyvgart Hytrulo passed a late-stage test in a family of rare autoimmune diseases, even though the drug missed the mark in a key patient subgroup. The subcutaneous drug
  endpoints · 3d ago
• Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug
  The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among multiple developers.
  biopharma_dive · 24d ago
• Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
  The star of the takeover is Forte Biosciences' investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.
  biospace · 24d ago
• STAT+: Argenx to buy Forte Biosciences for $2.2B
  Argenx plans to buy Forte Biosciences for $2.2 billion, expanding its pipeline of drugs that could treat multiple autoimmune diseases.
  stat · 24d ago
• Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug
  Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug.
  fiercebiotech · 24d ago
• Sanofi stops immune drug trial in latest research setback
  The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential blockbuster.
  biopharma_dive · 2mo ago
• 2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?
  Orphan drugs remain commercially durable, strategically relevant and supported by a strong pipeline
  biopharma_dive · 2mo ago
• Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
  Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.
  biopharma_dive · 3mo ago
• Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
  Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.
  biopharma_dive · 3mo ago